Floatz logo

Olaparib

BRIP1 Gene Mutation

Beth Israel Deaconess Medical CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the BRIP1 Gene Mutation cohort.

Asset / SponsorPhaseRating
Niraparib
Qian Qin
Phase 2CCC
Abemaciclib
University of California, Davis
Phase 2CCC
PREDNISONE TABLETS
Qian Qin
Phase 2CCC
Abiraterone Acetate
Qian Qin
Phase 2CCC
Docetaxel
Qian Qin
Phase 2CCC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →